

Synthesis and *in vitro* anticancer evaluation of novel pyridine derivatives bearing tetrahydronaphthalene scaffold

Eman Kh. Hamza,^a Nehal A. Hamdy,^{a*} Eman S. Zarie,^a Issa M. I. Fakhr,^a Ahmed H. M. Elwahy,^b and Hanem M. Awad^a

^aNational Research Centre, El-Buhouth St., Dokki, P.O. 12622, Giza, Egypt

^bDepartment of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

E-mail: drnehalhamdy63@hotmail.com


Received 09-05-2019

Accepted 02-06-2020

Published on line 02-16-2020

Abstract

A new series of tetralin-pyridine hybrids was synthesized in good yields starting from 2-(pyridin-2-yl)oxy)acetohydrazide as a synthon. The treatment of this acid hydrazide with six different aromatic aldehydes resulted in the formation of the corresponding arylidenehydrazides as *cis/trans* conformers, which upon treatment with thioglycolic acid afforded 4-thiazolidinone derivatives. The acid hydrazide synthon also reacted with a variety of activated reagents to give the corresponding tetralin-pyridine derivatives in good yields. The *in vitro* cytotoxic activity of the new compounds were tested showing that these compounds appeared as promising active anti-cancer compounds.



Keywords: Tetralin, pyridine, benzylidenehydrazides, thiazolidinones, anticancer activity

Introduction

Cancer diseases are considered as the second common cause of death after heart disease worldwide.^{1,2} Chemotherapy is still one of the most important roles for cancer treatment. The major issue in the use of chemotherapeutics is the undesirable side effects. Therefore, search for new agents, not only for the treatment of cancer but also to overcome cancer resistance to drug treatment as well as to avoid drug side effects, is a challenge goal.

In this respect, many pyridine derivatives have been synthesized and their biological and chemotherapeutic activities have been investigated and reported.³⁻⁶ The pyridine moiety is found in many pharmaceutical drugs such as Isoniazid (anti-tuberculosis drug), Omeprazole (antihistaminic drug), Pioglitazone (anti-diabetic drug), Sorafenib and Regorafenib (anticancer drugs) as well as in many agrochemicals such as pyridinenitrile (fungicide), Nitapyrin (bactericide) and Picloram (herbicide). The pyridine motif is also present in a number of biologically active molecules including niacin (vitamin B3), pyridoxine (vitamin B6) and the toxic alkaloid (nicotine) (Figure 1).⁷⁻¹¹




Figure 1. Structures of some pyridine containing pharmaceutical drugs, agrochemicals and a number of biologically active molecules.

Moreover, tetrahydronaphthalene derivatives have attracted much attention in the medicinal field because of their broad range of pharmacological properties.¹²⁻¹⁸ Furthermore, tetrahydronaphthalene (tetralin) is also an efficient ring, which is found in the structures of some anticancer drugs such as doxorubicin and epirubicin (Figure 2).¹⁹





Figure 2. Tetralin containing anticancer drugs

Motivated by these findings and in conjunction with our ongoing research work on pyridine chemistry,²⁰⁻²⁵ as well as on the development of new anticancer agents with improved efficacy, high selectivity and minimum toxicities,²⁶⁻²⁸ we report herein the synthesis of novel derivatives based on 5,6,7,8-tetrahydronaphthalene-pyridine scaffolds as new hybrid molecules. The anticancer activities of the new compounds have also been evaluated.

Results and Discussion

Chemistry

The starting 2-(pyridin-2-yl)oxy)acetohydrazide **7** was synthesized in a good yield using the synthetic route outlined in scheme 1. Thus, according to our reported procedure,²⁹ 2-oxo-6-(tetrahydronaphthalen-2-yl)-1,2-dihydropyridine-3-carbonitrile **4** was obtained in a good yield by a four-component reaction of 2-acetyl-5,6,7,8-tetrahydronaphthalene **1**³⁰ with 4-fluorobenzaldehyde **2a**, ethyl cyanoacetate **3** and excess ammonium acetate in *n*-butanol at reflux. Reaction of **4** with ethyl bromoacetate **5** in the presence of anhydrous K_2CO_3 in dry acetone afforded ethyl 2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetate **6**, which upon treatment with hydrazine hydrate in absolute ethanol afforded the desired acetohydrazide **7**³¹ (Scheme 1).




Scheme 1. Synthesis of the acetohydrazide compound **7**.

Hydrazides are useful important intermediates and their condensation products are reported to possess a wide range of biological activities.^{32,33} In this work, the acetohydrazide **7** was used as a versatile precursor for the synthesis of novel interesting pyridine derivatives, *via* its reactions with a variety of reagents (Scheme 2-6).


New Schiff base derivatives **8a-f** were obtained by condensation of acetohydrazide derivative **7** with a series of aromatic aldehydes namely, 4-fluorobenzaldehyde **2a**, benzaldehyde **2b**, 4-bromobenzaldehyde **2c**, 4-chlorobenzaldehyde **2d**, 4-cyanobenzaldehyde **2e** and 4-methoxybenzaldehyde **2f** in ethanol and a catalytic amount of glacial acetic acid at reflux. The IR spectra of **8a-f** revealed absorption bands between 3212-3198 and 2224-2220, 1681-1664 cm^{-1} assignable for NH, CN and C=O groups, respectively, while no absorption bands for the NH_2 group in their spectra were detected. The disappearance of the absorption bands due to NH_2 in both IR as well as in the ^1H NMR spectra of **8** confirmed that the hydrazide- NH_2 completely reacted with $-\text{CHO}$ groups of the used aldehydes leading to the formation of the corresponding Schiff bases (scheme 2). The ^1H and ^{13}C NMR spectra of the hydrazone derivatives **8a-f** displayed additional signals at the aromatic region due to aromatic ring protons derived from the aldehyde moiety, in addition to the characteristic signals belonging to benzylidene amino group ($\text{CH}=\text{N}$). The ^1H NMR spectra of compounds **8a-f** exhibited two sets of signals each belonging to the $-\text{OCH}_2$, $-\text{N}=\text{CH}$ and $-\text{NH}$ groups, of the *trans* and *cis* conformers, recorded between δ 5.61-5.64 and 5.07-5.12; 8.07-8.16 and 8.26-8.39; 11.64-12.01 and 11.80-12.19 ppm, respectively. In addition, the C_4 -proton of tetrahydronaphthalene appeared also as two doublets between 7.01-7.06 and 7.06-7.11 ppm, corresponding to *trans* and *cis* conformers. The ratios of *trans/cis* conformers in each case were calculated by using ^1H NMR data. The ^{13}C NMR spectra of these compounds revealed also two sets of signals between 62.77-66.28 and 63.47-66.93 ppm; 139.97-142.98 and 141.99-145.92 ppm characteristic for the OCH_2 and $\text{N}=\text{CH}$ carbons, respectively. The C_4 of tetrahydronaphthalene was also observed as two sets of signals between δ 127.42-128.86 and 127.58-129.35 ppm. Moreover, the $-\text{OCH}_3$ protons of compound **8f** appeared as a singlet signal at δ 3.81 ppm in the ^1H NMR spectrum, and its ^{13}C NMR spectrum revealed the OCH_3 carbon at δ 56.07 ppm.

According to the literature,³⁴⁻³⁹ compounds having arylidene-hydrazide structure may exist as *E/Z* geometrical isomers around $\text{C}=\text{N}$ double bonds and *cis/trans* amide conformers (Scheme 3). It has been reported that, compounds containing imine bond exists at higher percentage of the geometrical *E* isomer about $-\text{C}=\text{N}$ double bond in dimethyl- d_6 sulfoxide solution.³⁷ While the *Z* isomer can be stabilized by an intramolecular hydrogen bond in less polar solvents. In compounds **8a-f**, no signal belonging to *Z* isomer was observed as the ^1H NMR data were obtained in dimethyl- d_6 sulfoxide solution. On the other hand, the dimethyl- d_6 sulfoxide solution of compounds **8a-f** indicated that among the *cis/trans* conformers of the geometrical *E* isomer, the *trans* conformer predominates.³⁴⁻³⁷



Scheme 2. Synthesis of compounds **8**, **11** and **13**.

The *cis/trans* conformer ratios of the *E* isomers can easily be determined by ¹H NMR integration. The data obtained from chemical shift values of OCH₂, N=CH, and NH protons of *cis/trans* conformers in the ¹H NMR and that obtained from chemical shift values of OCH₂ and N=CH carbons in the ¹³C NMR spectra of compounds **8** proved that the *E* isomers and *trans* conformer structures (I) are the dominant forms among the four possible structures.^{34–37} In the the *trans* conformers, the proton signals of N=CH and NH, are shifted upfield compared to those of the *cis* conformer. On the other hand, because of the steric hindrance, the OCH₂ proton signal of the *trans* conformer is shifted downfield compared to the that of the *cis* conformer.³⁴



Scheme 3. *E/Z* Geometrical isomers and *cis/trans* amide conformers of compounds **8a-f**.

Compounds **8a-f** containing imine bond have been synthesized for preparing other derivatives like thiazolidinones due to their broad spectrum of biological activities.⁴⁰ Thiazolidinone derivatives belong to the most frequently studied moieties of medicinal interest which attributed to the presence of thiazolidine in the structure of penicillin.⁴¹

The 4-thiazolidinone derivatives **11a** and **11c-f** were synthesized by refluxing the imine **8a** and **8c-f** with thioglycolic acid **9** in dry benzene according to the reported method (Scheme 2).⁴² The formation of thiazolidinone derivatives were assumed to occur by the addition of the SH group of thioglycolic acid to the CH=N bond of the hydrazine moiety of **8a** and **8c-f** to yield the corresponding acyclic non-isolable intermediates **10** which underwent the elimination of water molecule by intramolecular cyclization to afford the final cyclocondensation products **11**.⁴³

The structures of the newly synthesized compounds were confirmed by IR, ¹H-NMR and ¹³C-NMR as well as elemental analyses. The IR spectra of compounds **11a** and **11c-d** showed absorption bands at 3435-3441 (NH), 2220-2224 (CN), 1711-1729 (C=O of 4-thiazolidinone ring) and 1675-1685 cm⁻¹ (C=O amide). The ¹H-NMR spectra for **11a** and **11c-f** showed the two methylene protons of the thiazolidinone ring as doublet of doublets signals at δ 3.73-3.77, 3.85-3.93 ppm and the methine protons as singlet signals at δ 5.68-5.83 ppm.

The OCH_2 groups appeared as doublet of doublets signals between δ 5.00-5.06, 5.09-5.15 ppm and the NH groups appeared as singlet signals at δ 10.57-10.82 ppm. ^{13}C NMR spectral data also supports the formation of compounds **11a** and **11c-f**. Thus, the two carbonyl groups were observed between δ 166.55-167.11 and 168.21-168.87 ppm; the SCH_2CO and the NCHS carbons appeared at δ 32.71-35.39 ppm and at δ 59.65-65.38 ppm, respectively.


Moreover, condensation of **7** with isatin **12** in ethanol at reflux in the presence of a catalytic amount of glacial acetic acid yielded the hydrazone derivative **13**. The structure of **13** was confirmed by IR spectrum which showed absorption bands at 3427 and 3212 cm^{-1} due to (2NH) and at 2228, 1709 and 1657 cm^{-1} due to CN, C=O of isatin ring and C=O (amide), respectively. Moreover, the ^1H NMR spectrum of **13** showed a D_2O -exchangeable NH signal at δ 11.35 ppm characteristic for the NH proton of the isatin moiety. On the other hand, the hydrazine function proton (=N–NH–) appeared as two singlet signals at δ 12.78 and 13.40 ppm, respectively, due to *trans/cis* conformers. Furthermore, the ^{13}C NMR spectrum of this compound showed two carbonyl groups at δ 167.90 and 168.75 ppm, confirming the structure of **13** (Scheme 2).

Fusion of a mixture of acetic acid hydrazide **7** and acetic anhydride **14** afforded the new acetic-*N'*-acetyl-2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetohydrazonic anhydride **15** (Scheme 4). The IR spectrum of **15** revealed the presence of two bands at 1742 and 1670 cm^{-1} due to the acetoxy C=O and the amide C=O, respectively, which is in agreement with that reported in the literature.⁴⁴ In addition, the ^1H NMR spectrum of **15** showed two methyl protons at δ 2.34 ppm and at δ 2.35 ppm for NHCO-CH_3 and for OCO-CH_3 , respectively. Likewise, the ^{13}C NMR spectrum of **15** showed the two methyl carbons of the acetoxy and the acetamide groups at δ 22.49 and 22.58 ppm, respectively, in addition to the two carbonyl groups at δ 168.63 and 170.56 ppm, respectively.

Benzoylation of **7** was achieved *via* its reaction with benzoyl chloride **16** in refluxing pyridine to give *N'*-(2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetyl)benzohydrazide **17** (Scheme 4).

The IR spectrum of compound **17** revealed strong absorption bands at ν 3432, 3230, 1728 and 1716 cm^{-1} attributable to two NH groups and two C=O groups, respectively. The ^1H NMR spectrum of compound **17** revealed two singlets at δ 10.37 and δ 10.46 ppm assigned to the two NH protons, in addition to multiplet signals in the region δ 7.45-7.99 ppm characteristic to the aromatic protons. ^{13}C NMR spectrum of **17** gave a further evidence for its structure as it showed the two carbonyl groups at δ 165.36 and 168.08 ppm, respectively.

Our study was extended to include the synthesis of 2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-*N'*-formylacetohydrazide **19** in good yields by heating acetohydrazide **7** with formic acid **18** at reflux (Scheme 4). The IR spectrum of compound **19** displayed an absorption band at 1724 cm^{-1} corresponding to the carbonyl C=O of the formyl group, which appeared in the ^{13}C NMR spectrum at δ 169.7 ppm. Its ^1H NMR spectrum revealed a singlet at δ 8.04 ppm assigned to the formyl proton.




Scheme 4. Synthesis of compounds **15**, **17**, **19** and **20**.

Methyl (pyridin-2-yl)oxyacetylhydrazine-1-carbodithioate **20** was also synthesized by the reaction of acetohydrazide **7** with carbon disulfide and methyl iodide in ethanolic solution in the presence of triethylamine (TEA), according to the reported method.⁴⁵ The structure of this compound was confirmed according to its correct analytical and spectroscopic data. The ^1H NMR spectrum of **20** showed signals at δ 10.76 and at δ 10.80 assigned for two NH protons and at 2.56 ppm corresponding to $-\text{SCH}_3$ group while its carbon appeared at δ 19.56 ppm in the ^{13}C NMR in addition to the $\text{C}=\text{S}$ which appeared at δ 205.10 ppm. Further structural verification was obtained from its mass spectroscopy, which showed the correct molecular ion peak at m/z 506.30 (M^+ , 100).

The acetohydrazide derivative **7** is also a very useful intermediate for further cyclocondensation reactions. Thus, cyclocondensation of **7** with acetylacetone **21** afforded the corresponding dimethylpyrazole derivative **23** as a single product *via* initial formation of the intermediate hydrazone **22**⁴³ (Scheme 5). The structure of compound **23** was confirmed based on the IR, ^1H NMR, ^{13}C NMR and mass spectral data, which were in agreement with the assigned structure. Thus, the absence of signals corresponding to NH, NH_2 protons in both the IR and ^1H NMR spectra confirmed that they were involved in the cyclization. Also, ^1H -NMR spectrum of **23** showed two singlets at δ 2.29 ppm and 2.45 ppm characteristic for the two CH_3 groups and a singlet at δ 6.35

ppm due to the H-4 of the pyrazole moiety. The ^{13}C NMR spectral of **23** revealed two characteristic singlets at δ 150.45 and 154.54 ppm for C3 and C5 of the pyrazole nucleus, respectively, in addition to the two methyl groups at δ 13.56 and 13.60 ppm.




Scheme 5. Synthesis of compounds **23** and **26**.

Furthermore, cyclocondensation of **7** with ethyl cyanoacetate in ethanol containing KOH at reflux gave a novel pyrazole derivative **26**. The formation of this compound proceeded through nucleophilic transformation to give the non-isolable acyclic intermediate **24**, followed by intramolecular cyclization *via* loss of ethanol molecule and tautomerization under the reaction conditions to give **25**. Subsequent acetylation of the amino group of **25** afforded the final product **26** in a good yield (Scheme 5). The structure of **26** was confirmed based on its correct analytical and spectral data. Its IR spectrum showed absorption bands at ν 3440 (OH), 3196 (NH), 2218 (CN) and 1606 ($\text{C}=\text{O}$) cm^{-1} . Also, the ^1H -NMR spectrum of compound **26** indicated the presence of a singlet signal integrated by three protons at δ 1.87 ppm for COCH_3 protons, and a singlet signal integrated by two protons at δ 5.11 ppm assigned to methylene protons. In addition, the aromatic protons as well as the pyrazole-H4 appeared at δ 7.42-7.93 ppm, in addition to signals at δ 9.89 and 10.21 ppm characteristic for NH and OH groups, respectively.

On the other hand, attempted synthesis of pyrazole **29** *via* the reaction of acetohydrazide **7** with [bis(methylthio)methylene] malononitrile **27** in ethanol was unsuccessful. The reaction gave instead the oxadiazole derivative **30**. The reaction seems to proceed *via* initial formation of the expected acyclic intermediate 2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-*N'*-(2,2-dicyano-1-(methyl-thio)vinyl)acetohydrazide **28**, which upon intramolecular nucleophilic cyclization by elimination of methylthiol molecule afforded the oxadiazol derivative **30** (Scheme 6).

The absence of sulfur element in the product of this reaction together with the disappearance of the amino NH_2 group in both IR and ^1H -NMR as well as the disappearance of $\text{C}=\text{O}$ in both the IR and ^{13}C -NMR spectra

confirmed the exclusion of **29**. Moreover, ^1H -NMR and ^{13}C -NMR spectra revealed the loss of the methylthio groups that can be considered as a strong evidence for the formation of the oxadiazol derivative **30** which in agreement with that related in the literature.⁴³



Scheme 6. Synthesis of compound **30** from acetohydrazide **7**.

1. *In-vitro* cytotoxicity activities

The *in vitro* cytotoxic activity of twenty compounds of the synthesized compounds were evaluated against human colorectal carcinoma cell line (HCT116) and human breast cancer cell line (MCF-7) using MTT assay. The percentages of the viable cells was measured and compared to that obtained by the positive control Doxorubicin® (Fig.3,4). The cytotoxic activities of the tested compounds were also expressed as IC_{50} μM values (the dose that reduces survival to 50%). Regarding the activity of the evaluated compounds against HCT116 cancer cells, the results in Table 1 showed that the compounds possessed high cytotoxicity approximately equal to that obtained by doxorubicin (IC_{50} ; 7.7-9.0 μM , IC_{50} doxorubicin; 8.0 μM). Concerning MCF-7 cancer cells, it is evident that there is a wide variation in the cytotoxic potency of the tested compounds. Interestingly, the *N'*-formylacetohydrazide derivative **19** was approximately three times more active than DOX (IC_{50} ; 21.0 μM , IC_{50} doxorubicin; 68.4 μM). On the other hand, the activity decreased slightly by the acetohydrazonic anhydride derivative **15** to be twice that of the reference drug (IC_{50} ; 33.3 μM). Although linking the thiazolidinone ring to the oxyacetamide side chain as compound **11c** led to a decrease in the

potency, but it is still a promising antitumor agent comparable to DOX (IC_{50} ; 60.3 μM). It could be noted that the starting acetohydrazide compound **7** and its *p*-fluorophenyl Schiff's base analogue **8a** appeared to be slightly less potent cytotoxic candidates than DOX of IC_{50} values; 72.7 and 71.0 μM , respectively. The results also showed that the rest of the tested derivatives were weaker than DOX of IC_{50} values ranging from 78.0-110.9 μM . It could be concluded that tetralin-pyridine backbone is an interesting antitumor pharmacophore against the breast cancer cells (MCF-7). The above mentioned data reveal that all the evaluated compounds are more active against the human colon cancer type rather than against the human breast cancer type. Further structural modifications and optimization are needed to signify and widen the antitumor spectrum of the derivatives bearing tetralin-pyridine motif.




Figure 3. Dose dependent cytotoxicity percentages curve of the synthesized compounds on HCT-116 human cancer cells according to MTT assay.




Figure 4. Dose dependent cytotoxicity percentages curve of the synthesized compounds on MCF-7 human cancer cells according to MTT assay.

Table 1. Anticancer IC_{50} values of the tested compounds using MTT assay on the human colorectal and breast cancer cells

Compound	IC ₅₀ (μM) ± SD	
	HCT-116	MCF-7
7	8.5 ± 2.1	72.7 ± 5.8
8a	8.6 ± 2.3	71.0 ± 5.1
8b	8.0 ± 2.5	82.3 ± 6.5
8c	7.9 ± 1.9	102.3 ± 7.1
8d	8.1 ± 2.1	83.0 ± 6.1
8e	8.1 ± 1.8	71.9 ± 4.1
8f	7.7 ± 1.9	77.3 ± 3.7
11a	8.2 ± 2.1	87.9 ± 5.9
11c	9.0 ± 2.4	60.3 ± 5.1
11d	8.6 ± 2.3	88.8 ± 5.8
11e	8.3 ± 2.5	86.3 ± 4.7
11f	8.7 ± 2.8	71.0 ± 4.1
13	7.7 ± 1.6	110.9 ± 5.9
15	7.6 ± 1.5	33.3 ± 2.1
17	8.0 ± 1.9	94.0 ± 4.5
19	8.0 ± 2.1	21.0 ± 2.1
20	8.2 ± 2.3	79.4 ± 4.1
23	7.7 ± 1.9	131.5 ± 5.1
26	9.0 ± 2.3	94.5 ± 4.5
30	8.4 ± 2.1	78.0 ± 4.1
Doxorubicin	8.0 ± 2.1	68.4 ± 4.1

Conclusions

We successfully synthesized a new series of tetralin-pyridine hybrids in good yields by reacting 2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetohydrazide with a variety of reagents. The structures of the new compounds were confirmed by spectral data as well as elemental analyses. Study of the cytotoxic activity of the new compounds on HCT116 and MCF-7 human cancer cells using MTT assay revealed that these compounds are potent cytotoxic on the human colon cancer type and some of them showed good activities against breast cancer in vitro.

Experimental Section

1. Chemistry

General. All melting points are uncorrected and were taken in open capillary tubes using an Electro-thermal IA 9100 apparatus (Shimadzu, Japan). Microanalytical data were performed by Vario El-Mentar apparatus (Shimadzu, Japan), National Research Centre (NRC), Cairo, Egypt. The found values were within ±0.4% of the theoretical values. Infrared spectra (KBr) were recorded on a Perkin-Elmer 1650 spectrophotometer, NRC. ¹H NMR and ¹³C NMR spectra were determined on a Varian Mercury (run at 300 MHz for ¹H NMR and 75 MHz for ¹³C NMR) spectrometer (Varian, UK) (Faculty of Science, Cairo University, Egypt) or with a Bruker AVANCE 400

MHz spectrometer (Bruker) (Aalto university school of chemical engineering, Finland) with a 5 mm BBFO probe using deuterated dimethylsulfoxide DMSO as a solvent and the chemical shifts were expressed in δ ppm relative to TMS as an internal reference. Mass spectra were recorded at 70 eV on EI Ms-QP 1000 EX (Shimadzu, Japan), NRC. Follow-up of the reactions and checking of the purity of the compounds were made by TLC on silica gel precoated aluminum sheets (Type 60, F 254, Merck, Darmstadt, Germany) and the spots were detected by exposure to a UV lamp at 254 nm for a few seconds. The chemical names for the prepared compounds are given according to the IUPAC system. Compounds **1**²⁹, **4**, **6** and **7** were prepared as reported in the literature.^{30, 31}

General procedure for synthesis of compounds (8a-f)

A mixture of acetohydrazide (**7**) (0.4165 g, 1 mmol) and the appropriate aromatic aldehyde namely: 4-fluorobenzaldehyde (**2a**), benzaldehyde (**2b**), 4-bromobenzaldehyde (**2c**), 4-chlorobenzaldehyde (**2d**), 4-cyanobenzaldehyde (**2e**) and 4-methoxybenzaldehyde (**2f**) (1 mmol) in absolute ethanol (30 ml), was treated with acetic acid (0.5 mL). The clear solution was then heated at reflux for 6 h. The solid precipitate so formed during the course of the reaction on heating was collected by filtration, washed by hot ethanol and crystallized from acetic acid to give the benzylidene derivatives **8a-f**.

(2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-N'-(4-fluorobenzylidene)acetohydrazide (8a). Yield 64%; colorless crystals; m.p. 248-249 °C, the ratio of trans/cis conformers: 76/24; IR spectrum (KBr, cm⁻¹): 3198 (NH), 2925 (CH, alicyclic), 2221 (CN), 1674 (hydrazide C=O), 1600 (C=N), 1236 (C-F); ¹HNMR (400MHz, DMSO-d₆, δ ppm): 1.67 (br.s, 4H, 2CH₂ of tetrahydronaphthalene), 2.69 (m, 4H, 2CH₂ of tetrahydronaphthalene), 5.62, 5.09 (2s, 2H, OCH₂ trans/cis conformers), 7.06, 7.11 (2d, *J* 8.0 Hz, 8.0 Hz 1H, C₄-proton of tetrahydronaphthalene, trans/cis conformers), 7.44-7.55 (m, 4H, Ar-H), 7.73-7.86 (m, 7H, Ar-H), 8.11, 8.33 (2s, 1H, N=CH trans/cis conformers), 11.84, 12.03 (2s, 1H, NH exchangeable with D₂O trans/cis conformers); ¹³C NMR (101 MHz, DMSO) δ : 22.40 (2CH₂), 28.64, 28.77 (2CH₂), 66.28, 66.93 (OCH₂ trans/cis conformers), 115.77 (CN), 127.94, 128.17 (C-4 of tetrahydronaphthalene, trans/cis conformers), 142.84, 144.48 (N=CH trans/cis conformers), (91.43, 106.06, 115.77, 115.99, 124.43, 129.35, 131.07, 131.16, 132.17, 133.46, 137.08, 139.98, 155.24, 157.08, 162.56, 162.25) (22, Ar-C), 168.68 (hydrazide C=O); MS, m/z (%): 522.25 (M⁺, 7), 520.37 (M⁺-2, 2), 358.13 (41), 357.16 (100), 357.13 (71), 345.12 (44), 344.11 (100), 343.11 (31); Analysis calcd. for: C₃₁H₂₄F₂N₄O₂ (522.56): C, 71.25; H, 4.63; F, 7.27; N, 10.72; Found: C, 71.19; H, 4.58; F, 7.25; N, 10.79.

N'-Benzylidene-2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-acetohydrazide (8b). Yield 52%; light beige crystals; m.p. 260-261 °C; the ratio of trans/cis conformers: 75/25. IR (KBr, cm⁻¹): 3223 (NH), 2927 (CH, alicyclic), 2220 (CN), 1664 (hydrazide C=O), 1593 (C=N), 1239 (C-F); ¹HNMR (400MHz, DMSO-d₆, δ ppm): 1.66 (br.s, 4H, 2CH₂ of tetrahydronaphthalene), 2.67 (m, 4H, 2CH₂ of tetrahydronaphthalene), 5.62, 5.09 (2s, 2H, OCH₂ trans and cis conformers), 7.05, 7.10 (2d, *J*=8.0 Hz, 8.0 Hz 1H, C-4 proton of tetrahydronaphthalene, trans/cis conformers), 7.47 (d, *J* = 8 Hz, 5H, Ar-H), 7.71-7.88 (m, 7H, Ar-H + pyridine-H5), 8.12, 8.33 (2s, 1H, N=CH trans/cis conformers), 11.77, 11.95 (2s, 1H, NH exchangeable with D₂O trans/cis conformers); ¹³C NMR (101 MHz, DMSO) δ : 22.40, 22.48 (2CH₂), 28.64 (2CH₂), 63.50, 65.59 (OCH₂, trans/cis conformers), 113.49 (CN), 128.84, 129.35 (C-4 of tetrahydronaphthalene, trans/cis conformers), 139.97, 143.89 (N=CH trans/cis conformers), (91.24, 103.54, 115.75, 115.97, 124.44, 129.73, 131.07, 131.16, 133.45, 133.99, 135.11, 137.08, 155.24, 157.08, 161.08, 161.71, 163.22) (23, Ar-C), 168.68 (hydrazide C=O); MS, m/z (%): 504.48 (M⁺, 11), 503.18 (M⁺-1, 8), 77.13 (73), 63.09 (100), 62.13 (42.31). Analysis calcd. for C₃₁H₂₅FN₄O₂ (504.57) C, 73.79; H, 4.99; F, 3.77; N, 11.10; Found: C, 73.68; H, 4.87; F, 3.72; N, 11.21.

***N'*-(4-Bromobenzylidene)-2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetohydrazide (8c).** Yield 57%; light beige crystals; m.p. 236-237 °C, the ratio of trans/cis conformers: 78/22. IR spectrum (KBr, cm^{-1}): 3212 (NH), 2925 (CH, alicyclic), 2221 (CN), 1677 (hydrazide C=O), 1600 (C=N), 1240 (C-F); ^1H NMR (300MHz, DMSO- d_6 , δ ppm): 1.66 (br.s, 4H, 2CH_2 of tetrahydronaphthalene), 2.67 (m, 4H, 2CH_2 of tetrahydronaphthalene), 5.61, 5.09 (2s, 2H, OCH_2 trans/cis conformers), 7.04, 7.08 (2d, J 8.4 Hz, 8.4 Hz 1H, C-4 proton of tetrahydronaphthalene, trans/cis conformers), 7.46 (t, J 8.8 Hz, 2H, Ar-H), 7.65-7.84 (m, 9H, Ar-H+ Pyridine-H5), 8.09, 8.31 (2s, 1H, N=CH trans/cis conformers), 11.78, 11.92 (2s, 1H, NH exchangeable with D_2O trans/cis conformers); ^{13}C NMR (300 MHz, DMSO) δ : 22.31, 22.38 (2CH_2), 28.56, 28.69 (2CH_2), 63.42, 64.97 (OCH_2 , trans/cis conformers), 115.06 (CN), 128.59, 128.77 (C-4 of tetrahydronaphthalene, trans/cis conformers), 142.66, 145.92 (N=CH, trans/cis conformers), (91.42, 113.46, 115.58, 115.87, 123.06, 124.33, 127.81, 129.21, 130.89, 131.01, 131.70, 133.42, 137.04, 139.89, 155.15, 157.07, 161.42, 163.15, 164.71) (23, Ar-C), 168.59 (hydrazide C=O); MS, m/z (%): 584.11 ($\text{M}^+ + 1$, 4.4), 583.11 (M^+ , 6), 582.09 ($\text{M}^+ - 1$, 2), 385.08 (100), 357.12 (41), 344.11 (42). Analysis calcd. for: $\text{C}_{31}\text{H}_{24}\text{BrFN}_4\text{O}_2$ (583.46): C, 63.82; H, 4.15; Br, 13.69; F, 3.26; N, 9.60; Found C, 63.79; H, 4.05; Br, 13.58; F, 3.23; N, 9.79.

***N'*-(4-Chlorobenzylidene)-2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetohydrazide (8d).** Yield 67%; beige crystals; m.p. 231-232 °C, the ratio of trans/cis conformers: 72/28; IR spectrum (KBr, cm^{-1}): 3208 (NH), 2929 (CH, alicyclic), 2221 (CN), 1677 (hydrazide C=O), 1593 (C=N), 1239 (C-F); ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 1.67 (m, 4H, 2CH_2 of tetrahydronaphthalene), 2.65 (m, 4H, 4CH_2 of tetrahydronaphthalene), 5.61, 5.09 (2s, 2H, OCH_2 trans/cis conformers), 7.06, 7.11 (2d, J 8.0 Hz, 8.0 Hz 1H, C-4 proton of tetrahydronaphthalene, trans/cis conformers), 7.31 (t, J 8.8 Hz, 2H, Ar-H), 7.46 (t, J 8.8 Hz, 2H, Ar-H), 7.79- 7.86 (m, 7H, Ar-H + pyridine-H5), 8.11, 8.33 (2s, 1H, N=CH trans/cis conformers), 11.78, 11.96 (2s, 1H, NH exchangeable with D_2O trans/cis conformers); ^{13}C NMR (101 MHz, DMSO) δ : 21.07, 22.40 (2CH_2), 25.83 (2CH_2), 64.77, 65.81 (OCH_2 trans/cis conformers), 113.70 (CN), 128.49, 128.93 (C-4 of tetrahydronaphthalene, trans/cis conformers), 142.40, 145.18 (N=CH, trans/cis conformers), (91.86, 109.74, 115.98, 122.86, 129.35, 130.25, 131.16, 133.45, 134.77, 135.60, 136.79, 156.87, 158.47, 163.86) (22, Ar-C), 168.55 (hydrazide C=O); MS, m/z (%): 541.23 ($\text{M}^+ + 2$, 5), 539.13 (M^+ , 16), 123.13 (23.63), 59.14 (18.54), 10.15 (100), Analysis calcd. for: $\text{C}_{31}\text{H}_{24}\text{ClFN}_4\text{O}_2$ (539.01): C, 69.08; H, 4.49; Cl, 6.58; F, 3.52; N, 10.39; Found: C, 68.96; H, 4.38; Cl, 6.46; F, 3.48; N, 10.42.

2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-*N'*-(4-cyanobenzylidene)acetohydrazide (8e). Yield 70%; pale yellow crystals; m.p. 230-231 °C the ratio of trans/cis conformers: 70/30; IR spectrum (KBr, cm^{-1}): 3182 (NH), 2929 (CH, alicyclic), 2224 (CN), 1675 (hydrazide C=O), 1596 (C=N), 1226 (C-F); ^1H NMR (400MHz, DMSO- d_6 , δ ppm): 1.67 (br. s, 4H, 2CH_2 of tetrahydronaphthalene), 2.67 (m, 4H, 2CH_2 of tetrahydronaphthalene), 5.64, 5.12 (2s, 2H, OCH_2 trans/cis conformers), 7.05, 7.10 (2d, J =8.0 Hz, 8.0 Hz 1H, C-4 proton of tetrahydronaphthalene, trans/cis conformers), 7.45 (t, J 8.7Hz, 2H, Ar-H), 7.79-7.97 (m, 9H, Ar-H + pyridine-H5), 8.16, 8.39 (2s, 1H, N=CH trans/cis conformers), 12.01, 12.19 (2s, 1H, NH exchangeable with D_2O trans/cis conformers); ^{13}C NMR (101 MHz, DMSO) δ : 22.38, 22.46 (2CH_2), 28.63, 28.77 (2CH_2); 62.77, 63.47 (OCH_2 trans/cis conformers), 113.58 (CN), 118.62 (CN), 127.42, 127.58 (C-4 of tetrahydronaphthalene, trans/cis conformers), 139.97, 141.99 (N=CH trans/cis conformers), (91.43, 111.80, 115.95, 118.62, 116.66, 129.34, 131.06, 131.14, 132.13, 132.73, 133.43, 137.05, 138.43, 155.22, 157.07, 162.05, 163.17) (23C, Ar-C), 169.04 (hydrazide C=O); MS, m/z (%): 531.30 ($\text{M}^+ + 2$, 2), 530.36 ($\text{M}^+ + 1$, 3), 529.48 (M^+ , 6), 528.53 ($\text{M}^+ - 1$, 2), 431.20 (30), 368.43 (58), 358.22 (100), 357 (70), 327.30 (58); Analysis calcd. for: $\text{C}_{32}\text{H}_{24}\text{FN}_5\text{O}_2$ (529.58): C, 72.58; H, 4.57; F, 3.59; N, 13.22; Found: C, 72.47; H, 4.49; F, 3.53; N, 13.31.

2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-*N'*-(4-methoxybenzylidene)acetohydrazide (8f). Yield 56%; colorless powder; m.p. 222-223 °C, the ratio of trans/cis

conformers: 75/25; IR spectrum (KBr, cm^{-1}): 3204 (NH), 2928 (CH, alicyclic), 2221 (CN), 1681 (hydrazide C=O), 1603 (C=N), 1250 (C-F); ^1H NMR (400MHz, DMSO- d_6 , δ ppm): 1.69 (br.s, 4H, 2CH_2 of tetrahydronaphthalene), 2.69 (m, 4H, 2CH_2 of tetrahydronaphthalene), 3.81 (s, 3H, OCH_3), 5.39, 5.07 (2s, 2H, OCH_2 trans/cis conformers), 7.00-7.13 (m, 3H, C-4 proton of tetrahydronaphthalene trans/cis conformers + Ar-H), 7.013, 7.061, 7.113 (3d, 3H, C₄-proton of tetrahydronaphthalene trans/cis conformers + Ar-H), 7.42-7.91 (m, 9H, Ar-H + Pyridine-H5), 8.07, 8.26 (2s, 1H, N=CH trans/cis conformers), 11.64, 11.80 (2s, 1H, NH exchangeable with D_2O trans/cis conformers); ^{13}C NMR (101 MHz, DMSO) δ : 22.19 (2CH_2), 29.50 (2CH_2), 56.07 (OCH_3), 65.93, 66.91 (OCH_2 trans/cis conformers), 114.80 (CN), 128.86, 128.92 (C-4 of tetrahydronaphthalene, trans/cis conformers), 140.09, 142.36 (N=CH trans/cis conformers), (89.38, 106.08, 114.17, 116.73, 122.38, 126.46, 129.32, 130.34, 133.38, 134.00, 136.63, 156.93, 157.77, 162.75, 163.64, 164.06) (23, Ar-C), 168.07 (hydrazide C=O); MS, m/z (%): 536.47 ($\text{M}^+ + 2$, 83), 534.41 (M^+ , 90), 530.29 (28), 503.20 (39), 496.68 (35), 491.29 (44), 464.09 (45), 459.08 (46), 428.97 (37), 416.78 (33), 360.86 (44), 283.00 (55), 265.46 (72), 150.00 (39), 117.89 (29), 91.84 (43), 65.40 (100); Analysis calcd. for $\text{C}_{32}\text{H}_{27}\text{FN}_4\text{O}_3$ (534.59): C, 71.90; H, 5.09; F, 3.55; N, 10.48; Found: C, 71.82; H, 5.03; F, 3.49; N, 10.57.

General procedure for synthesis of thiazolidinone 11a and 11c-f. A solution of Schiff bases (**8a** and **8c-f**) (0.001 mol), and thioglycolic acid (**9**) (0.165 g; 0.0015 mol), in dry benzene (50) mL was heated at reflux for 6 h. Progress of the reaction was checked by TLC using benzene-ether as eluent. After evaporation of the solvent under reduced pressure, the resulting viscous liquid was treated with saturated sodium bicarbonate solution to remove unreacted thioglycolic acid. The product separated out was washed with water, dried and recrystallized from ethanol to afford compounds **11a** and **11c-f**.

2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)acetamide (11a). Yield 65%; beige crystals; m.p. 240-242 °C; IR spectrum (KBr, cm^{-1}): 3439 (NH), 2924 (CH, alicyclic), 2223 (CN), 1724 (C=O of 4-thiazolidinone ring), 1677 (C=O amide), 1600 (C=N), 1228 (C-F); ^1H NMR (400MHz, DMSO- d_6 , δ ppm): 1.77, 2.79 (2 br.s, 4H, 4H, 4CH_2 of tetrahydronaphthalene), 3.73, 3.89 (2d, 2H, thiazolidinone- CH_2), 5.03, 5.10 (2d, 2H, 2-methylene-H of OCH_2), 5.74 (s, 1H, thiazolidinone-H-2), 7.02-7.11 (m, 2H, Ar-H), 7.32 -7.48 (m, 4H, Ar-H), 7.70-7.95 (m, 6H, Ar-H + pyridine-H5), 10.63 (s, 1H, NH exchangeable with D_2O); ^{13}C NMR (101 MHz, DMSO) δ : 22.61 (2CH_2), 28.77 (2CH_2), 35.34 (SCH_2CO), 64.28 (NCHS), 65.80 (OCH_2), 97.11 (C-CN), 114.37 (CN), 161.93 (C-F), 167.11 (C=O), 168.56 (C=O), (104.46, 115.77, 124.53, 127.38, 129.40, 131.02, 132.06, 133.17, 134, 135.12, 136.01, 157.35, 157.76, 163.15, 164.89) (21, Ar-C); MS, m/z (%): 596.65 (M^+ , 8), 97.17 (8.), 85.17 (26.84), 71.15 (82.42), 57.14 (100); Analysis calcd. for: $\text{C}_{33}\text{H}_{26}\text{F}_2\text{N}_4\text{O}_3\text{S}$ (596.65): C, 66.43; H, 4.39; F, 6.37; N, 9.39; S, 5.37; found: C, 66.38; H, 4.28; F, 6.17; N, 9.48; S, 5.24.

N-(2-(4-Bromophenyl)-4-oxothiazolidin-3-yl)-2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetamide (11c). Yield 66%; light beige crystals; m.p. 246-248 °C; IR spectrum (KBr, cm^{-1}): 3441 (NH), 2925 (CH, alicyclic), 2220 (CN), 1715 (C=O of 4-thiazolidinone ring), 1675 (C=O amide), 1598 (C=N), 1230 (C-F); ^1H NMR (400MHz, DMSO- d_6 , δ ppm): 1.75 (br. s, 4H, 2CH_2 of tetrahydronaphthalene), 2.79 (br.s, 4H, 2CH_2 of tetrahydronaphthalene), 3.73, 3.89 (2d, 2H, thiazolidinone- CH_2), 5.04, 5.11 (2d, 2H, 2-methylene-H of OCH_2), 5.72 (s, 1H, thiazolidinone-H-2), 7.08 (d, J 8.0 Hz, 1H, Ar-H), 7.23 (d, J 8.0 Hz, 2H, Ar-H), 7.38-7.48 (m, 4H, Ar-H), 7.74-7.95 (m, 5H, Ar-H + pyridine-H5), 10.72 (s, 1H, NH exchangeable with D_2O); ^{13}C NMR (101 MHz, DMSO) δ : 22.53 (2CH_2), 28.80 (2CH_2), 34.65 (CH_2), 60.82 (NCHS), 63.59 (OCH_2), 115.07 (CN), (91.65, 107.47, 115.77, 120.60, 125.01, 127.92, 129.28, 130.14, 131.01, 131.34, 133.21, 133.33, 134.90, 136.43, 138.28, 155.01, 157.30, 162.61, 164.62) (22, Ar-C) 166.55 (C=O), 168.87 (C=O); MS, m/z (%): 656.18 (M^+ , 6), 440.16 (5), 385.14 (5), 357.94 (9), 344.18 (19), 257.94 (9), 184.01 (19), 89.07 (65),

77.09 (87), 76.09 (94.18), 75.09 (100); Analysis calcd. for: $C_{33}H_{28}BrFN_4O_3S$ (657.56): C, 60.28; H, 3.99; Br, 12.15; F, 2.89; N, 8.52; S, 4.88; found: C, 60.19; H, 3.89; Br, 12.11; F, 2.78; N, 8.61; S, 4.83.

***N*-(2-(4-Chlorophenyl)-4-oxothiazolidin-3-yl)-2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-**

tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetamide (11d). Yield 62%; light beige crystals; m.p. 240-242 °C; IR spectrum (KBr, cm^{-1}): 3439 (NH), 2925 (CH, alicyclic), 2220 (CN), 1711 (C=O of 4-thiazolidinone ring), 1677 (C=O amide), 1600 (C=N), 1231 (C-F); 1H NMR (400 MHz, DMSO- d_6 , δ ppm): 1.77 (br.s, 4H, $2CH_2$ of tetrahydronaphthalene), 2.79 (br.s, 4H, $2CH_2$ of tetrahydronaphthalene), 3.74, 3.89 (2d, 2H, thiazolidinone- CH_2), 5.06, 5.09 (2d, 2H, 2-methylene-H of OCH_2), 5.74 (s, 1H, thiazolidinone-H-2), 7.09 (d, J 8.0 Hz, 1H, Ar-H), 7.27-7.30 (m, 3H, Ar-H), 7.46 (t, J 8.0 Hz, 3H, Ar-H), 7.75-7.84 (m, 4H, Ar-H), 7.90 (s, 1H, pyridine-H5), 10.67 (s, 1H, NH exchangeable with D_2O); ^{13}C NMR (101 MHz, DMSO) δ : 22.53 ($2CH_2$), 28.77 ($2CH_2$), 32.71 (SCH_2CO), 62.00 ($NCHS$), 69.33 (OCH_2), 97.80 ($C-CN$), 114.33 (CN), 132.97 (C-Cl), 166.62 (C=O), 168.21 (C=O), (106.72, 116.11, 121.83, 126.40, 128.43, 129.43, 131.25, 133.17, 134.22, 136.22, 140.98, 155.91, 157.29, 162.74, 165.02) (21, Ar-C); MS, m/z (%): 613.99 (M^+ , 14), 210.15 (72.02), 123.12 (23), 71.15 (36.49), 69.18 (100); Analysis calcd. for: $C_{33}H_{26}ClFN_4O_3S$ (613.10): C, 64.65; H, 4.27; Cl, 5.78; F, 3.10; N, 9.14; S, 5.23; found: C, 64.58; H, 4.19; Cl, 5.69; F, 2.99; N, 9.26; S, 5.19.

2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-*N*-(2-(4-cyanophenyl)-4-oxothiazolidin-3-yl)acetamide (11e). Yield 60%; light green crystals; m.p. 190-192 °C; IR spectrum (KBr, cm^{-1}): 3435 (NH), 2928 (CH, alicyclic), 2224 (CN), 1729 (C=O of 4-thiazolidinone ring), 1685 (C=O amide), 1595 (C=N), 1233 (C-F); 1H NMR (400MHz, DMSO- d_6 , δ ppm): 1.75 (br. s, 4H, $2CH_2$ of tetrahydronaphthalene), 2.77 (br. s, 4H, $2CH_2$ of tetrahydronaphthalene) 3.75, 3.93 (2d, 2H, thiazolidinone- CH_2), 5.05, 5.09 (2d, 2-methylene-H of OCH_2), 5.83 (s, 1H, thiazolidinone-H-2), 7.05 (d, J 8.1 Hz, 1H, Ar-H), 7.45 (d, J 8.0 Hz, 4H, Ar-H), 7.62-7.66 (m, 2H, Ar-H), 7.74- 7.94 (m, 5H, Ar-H + pyridine-H5), 10.82 (s, 1H, NH exchangeable with D_2O); ^{13}C NMR (101 MHz, DMSO) δ : 22.55 ($2CH_2$), 28.84 ($2CH_2$), 35.39 (CH_2), 59.65 ($NCHS$), 61.45 (OCH_2), 97.45 ($C-CN$), 111.48 ($C-CN$), 115.76 (CN), 121.23 (CN), 168.76 (2 C=O), (101.66, 117.26, 123.91, 127.58, 128.20, 130.62, 132.33, 134.63, 136.42, 137.93, 157.77, 161.70, 164.75, 166.60), (21, Ar-C); MS, m/z (%): 605.69 ($M^+ + 2$, 3), 603.17 (M^+ , 10), 430.24 (76), 357.21 (100), 102.13 (61), 76.03 (88); Analysis calcd. for: $C_{34}H_{28}FN_5O_3S$ (603.67) C, 67.65; H, 4.34; F, 3.15; N, 11.60; S, 5.31; found: C, 67.50; H, 4.22; F, 3.05; N, 11.68; S, 5.22.

2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-*N*-(2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)acetamide (11f). Yield 73%; light beige crystals; m.p. 260-262 °C; IR spectrum (KBr, cm^{-1}): 3437 (NH), 2919 (CH, alicyclic), 2221 (CN), 1712 (C=O of 4-thiazolidinone ring), 1678 (C=O amide), 1608 (C=N), 1231 (C-F); 1H NMR (400MHz, DMSO- d_6 , δ ppm): 1.77, 2.79 (2 br.s, 4H, 4H, $4CH_2$ of tetrahydronaphthalene), 3.69 (s, 3H, OCH_3), 3.77, 3.85 (2d, 2H, thiazolidinone- CH_2), 5.00, 5.15 (2d, 2-methylene-H of OCH_2), 5.68 (s, 1H, thiazolidinone-H-2), 6.79 (d, J 8.0 Hz, 1H, Ar-H), 7.12, 7.22 (2d, J 8.0 Hz, J 8.0 Hz, 2H, Ar-H), 7.47 (d, J 8.0 Hz, 3H, Ar-H), 7.69-7.92 (m, 6H, Ar-H + pyridine-H5), 10.57 (s, 1H, NH exchangeable with D_2O); ^{13}C NMR (101 MHz, DMSO) δ : 22 ($2CH_2$), 29.72 ($2CH_2$), 32.77 (SCH_2CO), 56.56 (OCH_3), 65.38 ($NCHS$), 68.15 (OCH_2), 114.79 (CN), 166.62 (C=O), 168.55 (C=O), (91.09, 110.31, 113.76, 116.72, 119.97, 128.40, 129.52, 130.55, 131.65, 133.80, 134.90, 135.11, 136.63, 156.95, 157.15, 158.00, 162.54, 164.27) (22, Ar-C); MS, m/z (%): 608.69 (M^+ , 10), 91.15 (2), 85.19 (5), 71.18 (23), 57.15 (100); Analysis calcd. for: $C_{34}H_{29}FN_4O_4S$ (608.69): C, 67.09; H, 4.80; F, 3.12; N, 9.20; S, 5.27; found: C, 66.98; H, 4.75; F, 3.05; N, 9.29; S, 5.23.

2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-*N'*-(2-oxoindolin-3-ylidene)acetohydrazide (13). A mixture of the hydrazide **7** (0.416g, 1 mmol) and isatin **12** (0.147g, 1 mmol) in absolute ethanol (20 mL) containing glacial acetic acid (0.5 mL) was heated at reflux for 10 h. The precipitate

formed was collected by filtration while hot, washed with hot ethanol, dried and recrystallized from AcOH to afford compound **13**.

Yield: 86%; yellow crystals; m.p. 288-300 °C; IR spectrum (KBr, cm^{-1}): 3427, 3212 (NH), 2926 (CH, alicyclic), 2228 (CN), 1709 (C=O of isatin ring), 1657 (C=O amide), 1622 (C=N), 1228 (C-F); ^1H NMR (DMSO- d_6 , δ ppm): 1.66 (br.s, 4H, 2CH_2 of tetrahydronaphthalene), 2.68 (m, 4H, 2CH_2 of tetrahydronaphthalene), 5.30, 5.78 (br. 2s, 2H, OCH_2 trans/cis conformers), 6.97-7.13 (m, 3H, Ar-H), 7.38-7.49 (m, 4H, Ar-H), 7.82-7.87 (m, 5H, Ar-H+Pyridine-H5), 11.35 (s, 1H, NH exchangeable with D_2O), 12.78, 13.40 (br. 2s, 1H, NH exchangeable with D_2O trans/cis conformers); ^{13}C NMR (101 MHz, DMSO) δ : 22.95 (2CH_2), 29.12 (2CH_2), 66.39 (OCH_2), 114.66 (CN), (93.58, 108.22, 116.26, 116.43, 116.48, 119.47, 123.20, 123.67, 128.45, 129.80, 131.69, 133.59, 133.84, 135.17, 136.13, 143.04, 155.90, 156.65, 163.09, 164.77) (2 Ar-C), 167.90, 168.75 (2 C=O); MS, m/z (%): 545.57 (M^+ , 6), 385.09 (76), 384.09 (30), 358.10 (100), 357.07 (83); Analysis calcd. for $\text{C}_{32}\text{H}_{24}\text{FN}_5\text{O}_3$ (545.57): C, 70.45; H, 4.43; F, 3.48; N, 12.84; Found: C, 70.39; H, 4.38; F, 3.43; N, 12.92.

Acetic-*N'*-acetyl-2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetohydrazonic anhydride (15).

A mixture of acetohydrazide **7** (0.416 g, 0.001 mol) and acetic anhydride (5 mL) was heated at reflux for 6 h. After cooling, the reaction mixture was treated with ethanol and the formed precipitate was filtered, washed with ethanol. The dried crude product was crystallized from EtOH/DMF to give **15**.

Yield % 80; colorless crystals; m.p. 200-202 °C; IR spectrum (KBr, cm^{-1}): 3301 (NH), 2938 (CH, alicyclic), 2224 (CN), 1742 (acetoxycarbonyl C=O), 1670 (amide C=O), 1590 (C=N), 1204 (C-F); ^1H NMR (300 MHz, DMSO- d_6 , δ ppm): 1.71 (br. s, 4H, 2CH_2 of tetrahydronaphthalene), 2.34 (s, 3H, $\text{NHCO}-\text{CH}_3$), 2.35 (s, 3H, $\text{OCO}-\text{CH}_3$), 2.72 (m, 4H, 2CH_2 of tetrahydronaphthalene), 5.69 (s, 2H, CH_2), 7.12 (d, J 7.8 Hz, 1H, Ar-H), 7.39 (t, J 8.7 Hz, 2H, Ar-H), 7.68 (s, 1H, Ar-H), 7.73-7.80 (m, 4H, Ar-H+Pyridine-H5), 10.59 (s, 1H, NH exchangeable with D_2O); ^{13}C NMR (101 MHz, DMSO) δ : 22.49, 22.58 (2CH_3), 24.48 (2CH_2), 28.68 (2CH_2), 65.93 (OCH_2), 114.78 (CN), 162.84 (C=NNH), (91.57, 104.31, 115.77, 115.98, 124.72, 128.25, 129.37, 129.74, 131.19, 131.59, 133.29, 136.24, 137.22, 156.44, 157.48, 163.31, 164.41) (18C, Ar-C), 168.63, 170.78 (2C=O); MS, m/z (%): 500.23 (M^+ , 14), 458.40 (9), 385.18 (23.44), 344.15 (33.16), 98.02 (57.31), 56.08 (100); Analysis Calcd. for $\text{C}_{28}\text{H}_{25}\text{FN}_4\text{O}_4$ (500.53), C, 67.19; H, 5.03; F, 3.80; N, 11.19; Found: C, 67.08; H, 4.95; F, 3.74; N, 11.28.

***N'*-(2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetyl)benzohydrazide (17).**

A mixture of hydrazide **7** (0.416 g, 0.001 mol) and benzoyl chloride **16** (0.1405 g, 0.001 mol) in 10 mL pyridine was heated at reflux for 24 h then cooled and poured onto ice/water acidified with HCl. The obtained solid was filtered off, washed with water, dried and crystallized from EtOH/DMF to give the benzohydrazide derivative **17**.

Yield 81%; pale yellow crystals; m.p. 272-274 °C; IR (KBr, cm^{-1}): 3432, 3230 (2NH), 2925 (CH, alicyclic), 2222 (CN), 1728, 1716 (2C=O), 1607 (C=N), 1232 (C-F); ^1H NMR (300 MHz, DMSO- d_6 , δ ppm): 1.77 (br s, 4H, 2CH_2 of tetrahydronaphthalene), 2.81 (m, 4H, 2CH_2 of tetrahydronaphthalene), 5.22 (s, 2H, OCH_2), 7.16 (d, J = 8.4 Hz, 1H, Ar-H), 7.45-7.51 (m, 5H, Ar-H), 7.81-7.99 (m, 7H, Ar-H+Pyridine-H5), 10.37 (s, 1H, NH exchangeable with D_2O), 10.46 (s, 1H, NH exchangeable with D_2O); ^{13}C NMR (101 MHz, DMSO) δ : 21.57, 22.61 (2CH_2), 28.55, 29.18 (2CH_2), 65.98 (OCH_2), 115.78 (CN), (95.04, 108.72, 116.59, 123.29, 127.45, 128.48, 129.10, 130.61, 130.97, 133.11, 135.17, 136.76, 155.02, 155.64, 162.96) (23 C, Ar-C), 165.36, 168.08 (2 C=O); MS, m/z (%): 521.18 ($\text{M}^+ + 1$, 2), 520.19 (M^+ , 5), 519.26 ($\text{M}^+ - 1$, 2), 516.20 (2), 515.12 (3), 514.12 (2), 445.14 (37), 444.14 (100); Analysis calcd. for: $\text{C}_{31}\text{H}_{25}\text{FN}_4\text{O}_3$ (520.19): C, 71.53; H, 4.84; F, 3.65; N, 10.76; Found: C, 71.41; H, 4.78; F, 3.59; N, 10.88.

2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)-*N'*-formylacetohydrazide (19).

A mixture of **7** (0.832 g, 0.002 mol) and formic acid **17** (10 mL) was heated at reflux for 6 h. The

resulting solid on heating was collected by filtration, washed with hot ethanol, dried and recrystallized from ethanol/DMF to give **19**.

Yield 78%; off white crystals; m.p.: 244-246 °C; IR (KBr, cm^{-1}): 3440 (br, NH), 2922 (CH, alicyclic), 2220 (CN), 1724 (C=O), 1622 (C=O), 1247 (C-F); ^1H NMR (400 MHz, DMSO-d_6 , δ ppm): 1.76 (br.s, 4H, 2CH_2 of tetrahydronaphthalene), 2.77 (br.s, 4H, 2CH_2 of tetrahydronaphthalene), 5.08 (s, 2H, OCH_2), 7.15 (d, J 8.0 Hz, 1H, Ar-H), 7.44 (t, J 8.0 Hz, 2H, Ar-H), 7.81–7.91 (m, 5H, Ar-H+Pyridine-H5), 8.04 (s, 1H, $-\text{CH}=\text{O}$ aldehydic proton), 10.23, 10.51 (2s, 2NH, exchangeable with D_2O), ^{13}C NMR (101 MHz, DMSO) δ : 22.48 (2CH_2), 28.72 (2CH_2), 65.50 (OCH_2), 115.75 (CN), (97.13, 107.43, 115.96, 123.48, 128.04, 129.48, 131.08, 131.17, 133.50, 136.57, 137.23, 154.45, 155.29, 163.00) (17C, Ar-C), 161.63, 169.70 ($2\text{C}=\text{O}$); MS, m/z (%): 445.15 (M^++1 , 2), 444.12 (M^+ , 7), 403.08 (20), 402.08 (100), 358.11 (26), 357.09 (95), 344.20 (26), 343.06 (22); Analysis Calcd. for $\text{C}_{25}\text{H}_{21}\text{FN}_4\text{O}_3$ (444.47): C, 67.56; H, 4.76; F, 4.27; N, 12.61; Found: C, 67.58; H, 4.69; F, 4.23; N, 12.68

Methyl-2-((3-cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetyl)-hydrazine-1-carbodithioate (20). To a mixture of acetohydrazide **7** (0.416 g, 0.001 mol) and triethylamine (0.14 mL, 0.001 mol) in ethanol (15 mL), carbon disulfide (0.80 mL, 0.001 mol) was added dropwise. Methyl iodide (0.062 mL, 0.001 mol) was then added and the reaction mixture was stirred at room temperature for 30 min. Water (50 mL) was then added and the formed precipitate was filtered off, washed with water, dried and recrystallized from EtOH/DMF to give **20**.

Yield 68%; light brown crystals; m.p.: 210-212 °C; IR (KBr, cm^{-1}): 3439 (NH), 2925 (CH, alicyclic), 2219 (CN), 1717 (C=O), 1624 (C=N), 1232 (C-F); ^1H NMR (300 MHz, DMSO-d_6 , δ ppm): 1.76 (br.s, 4H, 2CH_2 of tetrahydronaphthalene), 2.56 (s, 3H, SCH_3), 2.76 (br.s, 4H, 2CH_2 of tetrahydronaphthalene), 5.16, 5.46 (2s, 2H, OCH_2), 7.15 (d, J = 8.1 Hz, 1H, Ar-H), 7.44 (t, J = 8.7 Hz, 2H, Ar-H), 7.78–7.90 (m, 5H, Ar-H + Pyridine-H5), 10.69 (s, 1H, NH, exchangeable with D_2O), 10.75 (s, 1H, NH, exchangeable with D_2O); ^{13}C NMR (101 MHz, DMSO) δ : 19.56 (SCH_3), 22.49 (2CH_2), 28.72, 29.74 (2CH_2), 64.30 (OCH_2), 113.55 (CN), (93.84, 105.54, 115.98, 122.39, 128.82, 129.10, 131.15, 132.28, 134.91, 136.43, 137.19, 155.98, 158.06, 163.11, 164.07) (17C, Ar-C), 168.14 (C=O), 201.65 (C=S); MS, m/z (%) : 510.68 (M^++4 , 52.52), 506.30 (M^+ , 100); Analysis calcd. for: $\text{C}_{26}\text{H}_{23}\text{FN}_4\text{O}_2\text{S}_2$ (506.61): C, 61.64; H, 4.58; F, 3.75; N, 11.06; S, 12.66; Found: C, 61.56; H, 4.49; F, 3.67; N, 11.19; S, 12.64.

2-(2-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-oxoethoxy)-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)nicotinonitrile (23). A mixture of acetohydrazide **7** (0.416 g, 0.001 mol) and acetyl acetone **20** (2 mL) was heated at reflux for 12 h. After cooling the fused mixture was treated with ethanol and filtered. The crude product was crystallized from ethanol to give compound **23**.

Yield: 65 %; Light brown crystals; m.p.: 190-192 °C; IR spectrum (KBr, cm^{-1}): 2929 (CH, alicyclic), 2219 (CN), 1726 (C=O), 1594 (C=N), 1227 (C-F); ^1H NMR (400 MHz, DMSO-d_6 , δ ppm): 1.76 (m, 4H, 2CH_2 of tetrahydronaphthalene), 2.29 (s, 3H, CH_3), 2.45 (s, 3H, CH_3), 2.72 (br. s, 4H, 2CH_2 of tetrahydronaphthalene), 5.90 (s, 2H, OCH_2), 6.35 (s, 1H, CH pyrazole), 7.05 (d, J 8.0 Hz, 1H, Ar-H), 7.46 (t, J 8.0 Hz, 2H, Ar-H), 7.60 (s, 1H, Ar-H), 7.68 (d, J 8.0 Hz, 1H, Ar-H), 7.69-7.87 (m, 3H, Ar-H + pyridine-H5); ^{13}C NMR (101 MHz, DMSO) δ : 13.56, 13.60 (2CH_3), 22.50 (2CH_2), 28.61 (2CH_2), 68.55 (OCH_2), 113.31 (CN), (92.26, 102.64, 110.31, 115.77, 115.98, 121.57, 127.72, 129.80, 129.80, 131.12, 132.76, 134.30, 135.65, 136.71, 150.45, 154.54, 156.53, 159.39, 163.83, 165.99) (20C, Ar-C), 168.16 (C=O); MS, m/z (%): 482.25 (M^++2 , 5), 480.79 (M^+ , 9), 478.74 (M^+-2 , 7), 292.15 (26), 210.13 (100), 57.11 (42); Analysis Calcd. For $\text{C}_{29}\text{H}_{25}\text{FN}_4\text{O}_2$: (480.54), C, 72.48; H, 5.24; F, 3.95; N, 11.66; Found: C, 72.35; H, 5.19; F, 3.89; N, 11.73.

N-(2-(2-((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)acetyl)-5-oxo-2,5-dihydro-1H-pyrazol-3-yl)acetamide (26). To a solution of acetohydrazide **7** (0.416 g, 0.001 mol) in 10% KOH solution (10 mL), ethyl cyanoacetate **3** (0.113 g, 0.001 mol) was refluxed in absolute ethanol (20 mL) for 10 h, then glacial acetic acid (5 mL) was added and the reaction mixture was heated at reflux for another 2 h. The

solid obtained upon cooling, dilution with water, acidification with conc. HCl and leaving in the fridge till next day was filtered, washed with water, dried and crystallized from acetic acid.

Yield 76%; off colorless crystals; m. p. 298-300 °C; IR spectrum (KBr, cm⁻¹): 3440 (OH), 3196 (NH), 2926 (CH, alicyclic), 2218 (CN), 1606 (br 2 C=O), 1230 (C-F); ¹H NMR (300 MHz, DMSO-d₆, δ ppm): 1.77 (br. s, 4H, 2CH₂ of tetrahydronaphthalene), 1.87 (s, 3H, COCH₃), 2.78 (m, 4H, 2CH₂ of tetrahydronaphthalene), 5.11 (s, 2H, OCH₂), 7.18 (d, *J* 8.4 Hz, 1H, Ar-H), 7.42-7.95 (m, 8H, Ar-H, CH-pyrazole and Pyridine-H5), 9.89 (s, 1H, NH exchangeable with D₂O), 10.21 (s, 1H, OH exchangeable with D₂O); ¹³C NMR (101 MHz, DMSO) δ: 20.90 (CH₃), 23.03, 23.10 (2CH₂), 28.69, 29.26 (2CH₂), 64.26 (OCH₂), 114.29 (CN), (92.28, 93.02, 106.69, 116.48, 123.83, 128.71, 129.96, 131.62, 132.67, 134.00, 136.02, 137.72, 140.44, 155.62, 157.61 163.58, 164.85) (19C, Ar-C), 166.49, 168.35 (2 C=O); MS, m/z (%): 525.35 (M⁺, 5), 385.15 (30), 357.16 (33), 85.10 (24), 74.12 (100); Analysis Calcd. for: C₂₉H₂₄FN₅O₄ (525.54): C, 66.28; H, 4.60; F, 3.62; N, 13.33; Found: C, 66.19; H, 4.53; F, 3.58; N, 13.39.

2-(5-(((3-Cyano-4-(4-fluorophenyl)-6-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridin-2-yl)oxy)methyl)-1,3,4-oxadiazol-2(3H)-ylidene)malononitrile (30). A mixture of the acetohydrazide **7** (0.416 g, 0.001 mol) and [bis(methylthio)methylene]-malononitrile (0.174 g, 0.001 mol), in absolute ethanol (30 mL) was heated at reflux for 12 h. The crystalline precipitate so formed under reflux was filtered off, washed with hot ethanol and crystallized from DMF to give the 1,3,4-oxadiazole **30**.

Yield 76%; Orange crystals; m.p. > 340 °C; IR spectrum (KBr, cm⁻¹): 3172 (NH), 2926 (CH, alicyclic), 2219 (CN), 1614 (C=N), 1228 (C-F), 1141 (C-O-C); ¹H NMR (300 MHz, DMSO-d₆, δ ppm): 1.63 (m, 4H, 2CH₂ of tetrahydronaphthalene), 2.72 (m, 4H, 2CH₂ of tetrahydronaphthalene), 5.13, 4.87, 5.26 (3s, 2H, OCH₂), 6.81, 6.98, 7.07 (3d, *J* 7.5 Hz, *J* 8.1 Hz, *J* = 8.1 Hz, 1H, C-4 of tetrahydronaphthalene), 7.44-7.54 (m, 3H, Ar-H), 7.70-7.90 (m, 4H, Ar-H + Pyridine-H5), 9.48, 10.46, 10.49 (3s, 1H, NH oxadiazole, exchangeable with D₂O); ¹³C NMR (101 MHz, DMSO) δ: 22.97 (2CH₂), 25.66 (CN-C-CN), 29.27 (2CH₂), 71.19, 71.48, 71.74 (OCH₂), 113.55 (2CN), 113.98 (CN), (93.60, 109.75, 116.32, 122.41, 126.60, 126.39, 127.78, 128.46, 130.91, 133.44, 134.28, 135.34, 136.09, 155.95, 156.78, 163.84, 164.48) (17C, Ar-C), 157.82 (C5 of oxadiazole), 208.62 (C2 of oxadiazole); MS: m/z (%): 490.50 (M⁺, 26), 358.15 (64), 357.14 (66), 344.13 (100), 343.12 (94.86); Analysis Calcd. for C₂₈H₁₉FN₆O₂ (490.50): C, 68.56; H, 3.90; F, 3.87; N, 17.13; Found: C, 68.49; H, 3.87; F, 3.83; N, 17.21.

2. In-vitro anticancer activities

The cytotoxicity activities on HCT116 (colorectal carcinoma) and MCF-7 (human breast adenocarcinoma) human cell lines was assessed using the 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.⁴⁶⁻⁴⁸ These cancer cell lines were purchased from ATCC (Rockville, MD, USA). The cells were cultured in a 96-well sterile microplate (5 × 10⁴ cells per well) at 37°C in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 U/mL of both penicillin and streptomycin in a 5% CO₂ humidified atmosphere. After 24 hours, the media were removed and a fresh serum-free medium (90 µL / well) were added together with 10 µL of series of each compound or doxorubicin[®] (positive control) concentrations in DMSO for 48 hours. Then, media were removed, MTT (40 µL of 2.5 mg/mL) was added to each well and incubated for 4 hours. 200 µL of DMSO were added to solubilize the formazan dye crystals (purple color). Using a SpectraMax[®] Paradigm[®] Multi-Mode microplate reader, the absorbance was measured at 570 nm. Each experiment was repeated on three different days and conducted in triplicate. The relative cell cytotoxicity was measured according to the following equation:

$$\% \text{ cytotoxicity} = (1 - A_s/A_b) * 100$$

Where; A_s = Absorbance of each sample and A_b = Absorbance of the blank. The probit analysis using the SPSS software program (version 20, SPSS Inc., Chicago, IL, USA) was used to determine each IC₅₀.

Acknowledgements

The authors thank the management and the authorities of National Research Centre, Dokki, Cairo, Egypt, for their kind support and constant encouragement. The authors are gratefully acknowledge the school of Chemical Engineering at Aalto University, Finland and German Research Foundation (DFG), Germany for performing NMR analyses.

Supplementary Material

Supplementary material related to this article, including Nuclear Magnetic Resonance (^1H and ^{13}C NMR) figures for compounds **8b**; **8c**; **8d**; **8e**; **11c**; **11d**; **15**; **17** and **23** are available in the online version of the text.

References

1. Zhang, J. Y. *Nat. Rev. Drug Disc.* **2002**, *1*, 101-102.
<https://doi.org/10.1038/nrd742>
2. Buolamwini, J. K. *Curr. Opin. Chem. Biol.* **1999**, *3*, 500-509.
[https://doi.org/10.1016/S1367-5931\(99\)80073-8](https://doi.org/10.1016/S1367-5931(99)80073-8)
3. Androutsopoulos, V. P.; Spandidos, D. A. *Oncol Rep.* **2018**, *39*(2), 519-524.
4. Xie, W.; Xie, S.; Zhou, Y.; Tang, X.; Liu, J.; Yang, W.; Qiu, M. *Eur. J. Med. Chem.* **2014**, *81*, 22-27.
<https://doi.org/10.1016/j.ejmech.2014.05.001>
5. Sajith, A. M.; Abdul Khader, K. K.; Joshi, N.; Reddy, M. N.; Syed, Ali Padusha, M.; Nagaswarupa, H. P.; Nibin Joy, M.; Bodke, Y. D.; Karuvalam, R. P.; Banerjee, R.; Muralidharan, A.; Rajendra, P. *Eur. J. Med. Chem.*, **2015**, *89*, 21-31.
<https://doi.org/10.1016/j.ejmech.2014.10.037>
6. Thapa, P.; Kadayat, T. M.; Park, S.; Shin, S.; ThapaMagar, T. B.; Bist, G.; Shrestha, A.; Na, Y.; Kwon, Y.; Lee, E. S. *Bioorg. Med. Chem.*, **2016**, *66*, 145-159.
<https://doi.org/10.1016/j.bioorg.2016.04.007>
7. Henkel, T.; Brunne, R. M.; Müller, H.; Reichel, F. *Angew. Chem. Int. Ed. Engl* **1999**, *38*, 643-647.
[https://doi.org/10.1002/\(SICI\)1521-3773\(19990301\)38:5<643::AID-ANIE643>3.0.CO;2-G](https://doi.org/10.1002/(SICI)1521-3773(19990301)38:5<643::AID-ANIE643>3.0.CO;2-G)
8. Santos, V. A. F. F. M.; Regasini, L. O.; Nogueira, C. R.; Passerini, G. D.; Martinez, I.; Bolzani, V. S.; Graminha, M. A. S.; Cicarelli, R. M. B.; Furlan M. J. *Nat. Prod* **2012**, *75*, 991-995.
<https://doi.org/10.1021/np300077r>
9. Bull, J. A.; Mousseau, J. J.; Pelletier, G.; Charette, A. B. *Chem. Rev.* **2012**, *112*, 2642-2713.
<https://doi.org/10.1021/cr200251d>
10. Goetz, A. E.; Garg, N. K. *Nature Chem.* **2013**, *5*, 54-60.
<https://doi.org/10.1038/nchem.1504>
11. Henry, G. D. *Tetrahedron* **2004**, *60*, 6043-6061.
<https://doi.org/10.1016/j.tet.2004.04.043>
12. Barker, M.; Clackers, M.; Copley, R.; Demaine, D.A.; Inglis, G.G.A.; Johnston, M. J.; Jones, H.T.; Haas, M.V.; House, D.; Loiseau, R.; et al. *J. Med. Chem.* **2006**, *49*, 4216-4231.

- <https://doi.org/10.1021/jm060302x>
13. Hamdy, N. A.; Gamal-Eldeen, A. M.; *Eur. J. Med. Chem.* **2009**, *44*, 4547-4556.
<https://doi.org/10.1016/j.ejmech.2009.06.023>
 14. Dong, Y.Z.; Shi, Q.; Nakagawa-Goto, K.; Wu, P.C.; Bastow, K.F.; Morris-Natschke, S.L.; Lee, K.H. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6289-6292.
<https://doi.org/10.1016/j.bmcl.2009.09.092>
 15. Zagahary, W.A. *Bull. Fac. Pharm. Cairo Univ.* **2007**, *45*, 391-400.
 16. Ates-Alagoz, Z.; Yildiz, S.; Buyukbingol, E. *Chemotherapy* **2007**, *53*, 110-113.
<https://doi.org/10.1159/000100011>
 17. Li, X.-N.; Lei, C.; Yang, L.-M.; Li, H.-M.; Huang, S.-X.; Du, X.; Pu, J.-X.; Xiao, W.-L.; Zheng, Y.-T.; Sun, H.-D. *Fitoterapia*, **2012**, *83*, 249-252.
<https://doi.org/10.1016/j.fitote.2011.11.006>
 18. Al-Abdullah, E.S. *Molecules* **2011**, *16*, 3410-3419.
<https://doi.org/10.3390/molecules16043410>
 19. Monneret, C. *Eur. J. Med. Chem.* **2001**, *36*, 483-493.
[https://doi.org/10.1016/S0223-5234\(01\)01244-2](https://doi.org/10.1016/S0223-5234(01)01244-2)
 20. Mohamed, M. F.; Darweesh, A. F.; Elwahy, A. H. M.; Abdelhamid, I. A. *RSC Adv* **2016**, *6*, 40900-40910.
<https://doi.org/10.1039/C6RA04974E>
 21. Sanad, S. M. H.; Kassab, R. M.; Abdelhamid, I. A.; Elwahy, A. H. M. *Heterocycles* **2016**, *92*, 910-924.
<https://doi.org/10.3987/COM-16-13441>
 22. Abdelhamid, I. A.; Darweesh, A. F.; Elwahy, A. H. M. *Tetrahedron Lett.* **2015**, *56*, 7085-7088.
<https://doi.org/10.1016/j.tetlet.2015.11.015>
 23. Kassab, R. M.; Elwahy, A. H. M.; Abdelhamid, I. A. *Monatshefte Für Chemie - Chem Mon* **2016**, *147*, 1227-1232.
<https://doi.org/10.1007/s00706-015-1644-z>
 24. Hebishy, A.M.S.; Abdelhamid, I.A.; Elwahy, A.H.M. *Arkivoc* **2018**, *v*, 97-108.
<https://doi.org/10.24820/ark.5550190.p010.367>
 25. Hebishy, A.M.S.; Abdelhamid, I.A.; Elwahy, A.H.M. *Arkivoc* **2018**, *v*, 109-123.
<https://doi.org/10.24820/ark.5550190.p010.498>
 26. Gamal-Eldeen, A. M.; Hamdy, N. A.; Abdel-Aziz, H. A.; El-Hussieny, E. A.; Fakhr, I. M. I. *Eur. J. Med. Chem.* **2014**, *77*, 323-333.
<https://doi.org/10.1016/j.ejmech.2014.03.021>
 27. Hamdy, N. A.; Gamal-eldeen, A. M.; Abdelaziz, H. A.; Fakhr, I M. I.; *Eur. J. Med. Chem.* **2010**, *45*, 463-470.
<https://doi.org/10.1016/j.ejmech.2009.10.027>
 28. Hamdy, N. A.; Anwar, M. M.; Abu-zied, K. M.; Awad, H. M. *Acta Pol. Pharm.* **2013**, *70*, 987-1001.
 29. Hamdy, N. A. *Egypt J. Chem.* **2005**, *48*, 749-758.
 30. Allinger, N.L.; Jones, E.S. *J. Org. Chem.* **1962**, *27*, 70-76.
<https://doi.org/10.1021/jo01048a018>
 31. Amin, K. M.; El-Zahar, M. I.; Anwar, M. M.; Kamel, M. M.; Mohamed, M. H. *Acta Pol. Pharm.* **2009**, *66*, 279-291.
 32. Sruthy, M. P., Meena Chandran, Krishnakumar, K. *Int. J. Med. Chem. Anal. IJMCA* **2016**, *6*, 56-60.
 33. Arief, M. M. H.; Aly, A. A.; Khalil, A. A.; Mohamed, H. I.; *J. Chem. Pharm. Res.*, **2014**, *6*, 327-331.
 34. Palla, G.; Predieri, G.; Domiano, P.; *Tetrahedron* **1986**, *42*, 3649-3654.
[https://doi.org/10.1016/S0040-4020\(01\)87332-4](https://doi.org/10.1016/S0040-4020(01)87332-4)

35. Demirbas, A. *Turk. J. Chem.* **2004**, 28, 311-323.
<https://doi.org/10.1260/0309524041590143>
36. Demirbas, N.; Karaoglu, S.A.; Demirbas, A.; Sancak, K. *Eur. J. Med. Chem.* **2004**, 39, 793-804.
<https://doi.org/10.1016/j.ejmech.2004.06.007>
37. Wyrzykiewicz, E.; Prukah, D. *J. Heterocycl. Chem.* **1998**, 35, 381-387.
<https://doi.org/10.1002/jhet.5570350221>
38. Galic, N.; Peric, B.; Kojic-Prodic, B.; Cimerman, Z. *J. Mol. Struct.* **2001**, 559, 187-194.
[https://doi.org/10.1016/S0022-2860\(00\)00703-1](https://doi.org/10.1016/S0022-2860(00)00703-1)
39. Bayrak, H.; Demirbas, A.; Karaoglu, S. A. Demirbas, N. *Eur. J. Med. Chem.* **2009**, 44, 1057-1066.
<https://doi.org/10.1016/j.ejmech.2008.06.019>
40. Waghmode, K. T. *J. Chem. Pharm. Res.*, **2014**, 6, 1101-1105.
41. Kanase, M. S.; Piste, P. B. *Int. J. Pharm. Sci. and Drug Res.* **2017**, 9(2), 38-43.
<https://doi.org/10.25004/IJPSTR.2017.090201>
42. Dawood, K. M. Farag, A. M. and Abdel-Aziz, H. A. *Heteroatom Chemistry* **2007**, 18(3), 294-300.
<https://doi.org/10.1002/hc.20298>
43. Abd El-All, M. M.; Halawa, A. H.; Hassan, A. A. El-H.; El-Nassag, M. A.; Abd El-Jaleel, G. A. El-R.; Eliwa, E. M.; Bedair, A. H. *J. Atoms and Molecules* **2013**, 3(4), 537-552.
44. Mohamed, F. K. *Pelagia Research Library Der Chemica Sinica*, **2010**, 1, 20-31.
45. Gobis, K.; Foks, H.; Bojanowski, K.; Augustynowicz-Kopec', E.; Napiórkowska, A. *Bioorg. Med. Chem.* **2012**, 20, 137-144.
<https://doi.org/10.1016/j.bmc.2011.11.020>
46. Abdel Latif, N. A.; Batran, R. Z.; Mohamed, S. F.; Khedr, M. A.; Mohamed Kobeasy, M.; Al- Shehri, S.; Awad, H. M. *Mini-Rev Med. Chem.* **2018**, 18, 1572-1587.
<https://doi.org/10.2174/1389557518666180423145246>
47. Soliman, H. A.; Kalmouch, A.; Awad, H. M.; Abdel Wahed, N. A. M. *Russ. J. Gen. Chem.* **2018**, 88, 1726-1733.
<https://doi.org/10.1134/S1070363218080273>
48. Kassem, A. F.; El-Kady, D. S.; Awad, H. M.; El-Sayed, W. A. *Mini-Rev Med. Chem.* **2018**;
49. <https://doi.org/10.2174/1389557519666181231121217>

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)